Danish biotech company Genmab (OMX: GEN) has been granted accelerated assessment for daratumumab in double refractory multiple myeloma by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency.
The marketing authorization application was submitted by Janssen-Cilag, a subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ), to which Genmab granted an exclusive worldwide license for daratumumab in August 2012.
The CHMP can grant accelerated assessment when a product is expected to be of major public health interest.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze